Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

DARK SECRETS: 3 | Rare Historical Photos

Five things you should know about the HIV epidemic

It is 40 years since Aids was first identified. Major strides have been made since the spread of the virus reached epidemic proportions in 1995 when 3.3 million people were infected with HIV and just under one million people died.

The Conversation

3 Biotech Stocks with Promising Pipelines to Watch

As breakthroughs in biotechnology accelerate, the sector is primed for significant expansion. With emerging trends like gene editing and precision medicine transforming healthcare, fundamentally solid biotech stocks such as Amgen (AMGN), Gilead Sciences (GILD), and Biogen (BIIB) are gaining traction. With promising innovations, these stocks could be prime investment opportunities.…

StockNews.com

Gilead Sciences Stock: Analyst Estimates & Ratings

Gilead Sciences has underperformed the broader market over the past year, but Wall Street analysts are moderately optimistic about the stock’s prospects.

Barchart

From analysis to the latest developments in health,
read the most diverse news in one place.

Option Volatility And Earnings Report For November 4 - 8

We have some important companies with Palantir, Super Micro computer, Block, Moderna, Qualcomm, Arista Networks, Gilead Sciences and Airbnb all set to report.

Barchart

3 Top Healthcare Stocks to Buy for Growth and Dividends

Investors seeking growth and dividend income in the healthcare sector may want to consider Eli Lilly, Gilead Sciences, and Amgen, which have delivered impressive returns and boast strong pipelines and strategic moves.

Barchart

Gilead Sciences’ Quarterly Earnings Preview: What You Need to Know

Gilead Sciences is scheduled to report its fiscal third-quarter earnings next month, and analysts anticipate a lower-double-digit drop in its EPS.

Barchart

HIV prevention: why a new injectable drug could be such a breakthrough – podcast

A new drug to prevent HIV infection is showing hugely promising results in clinical trials when injected every six months.

The Conversation

Read news from The Economist, FT, and more,
with one subscription

Is Gilead Sciences Stock Underperforming the Dow?

Despite Gilead Sciences' underperformance relative to the Dow Jones Industrial Average over the past year, Wall Street analysts remain moderately optimistic about the stock’s prospects.

Barchart

Do Wall Street Analysts Like Gilead Sciences Stock?

Gilead Sciences has underperformed the broader market over the past year, yet Wall Street analysts remain moderately bullish about the stock’s prospects.

Barchart

Gilead Sciences' Q2 2024 Earnings: What to Expect

Gilead Sciences is expected to release its fiscal second-quarter earnings next month, and analysts project a double-digit profit increase.

Barchart

HIV breakthrough: drug trial shows injection twice a year is 100% effective against infection

A large clinical trial in South Africa and Uganda has shown that a twice-yearly injection of a new pre-exposure prophylaxis drug gives young women total protection from HIV infection.

The Conversation

Is Gilead Sciences Stock Underperforming the Nasdaq?

Gilead Sciences has recently underperformed the broader Nasdaq Composite, but analysts are reasonably bullish about the stock’s outlook.

Barchart

3 Dividend Growth Stocks to Buy and Hold

These three dividend-paying growth stocks are worth a look at current levels as the odds rise for Fed rate cuts.

Barchart

Gilead Sciences Stock Outlook: Is Wall Street Bullish or Bearish?

Gilead Sciences has underperformed the broader market YTD, but Wall Street analysts are still cautiously optimistic about the stock’s prospects.

Barchart

Get all your
news in one place.

100's of premium titles.
One news app.

Barchart

Is Gilead Sciences Stock a Buy Near 52-Week Lows for Its 4% Yield?

Gilead Sciences stock has trailed the broader markets by a significant margin over the last eight years. Is this high-yield dividend stock a good buy right now?

StockNews.com

Gilead Sciences (GILD) Earnings Forecast and Gameplan

Gilead Sciences (GILD) boasts an impressive product portfolio and has surpassed the consensus estimate on the topline in each of the trailing four quarters. With the company gearing up to post its third quarter results, is GILD a wise investment now? Read on.

StockNews.com

Bionano Genomics (BNGO) vs. Gilead Sciences (GILD): Buy, Hold or Sell these Biotech Stocks?

As the biotech industry reaches new heights with innovation and the accessibility of big data, let us analyze whether biotech stocks Bionano Genomics and Gilead Sciences are a Buy, Hold, or Sell.

StockNews.com

3 Biotech Stocks With Some Major Value in Them

The worldwide need for healthcare and biotech products is experiencing a steady upsurge fueled by various factors, such as a heightened emphasis on personalized medicine. Therefore, it could be wise to explore three quality biotech stocks, Gilead Sciences (GILD), Biogen (BIIB), and Alkermes (ALKS), with significant value in them. Read…

Get all your
news in one place.

100's of premium titles.
One news app.

StockNews.com

3 Biotech Stocks Every Investor Wants

Given inelastic demand, rapid breakthroughs, and government initiatives, the biotech industry looks well-positioned to thrive. So, quality biotech stocks Gilead Sciences (GILD), Biogen (BIIB), and Alkermes (ALKS) could be worth owning. Read on.

Barchart

Markets Today: Stocks Slip Ahead of U.S. Debt Ceiling Talks

Morning Markets June E-Mini S&P 500 futures (ESM2 3) this morning are down -0.26%, and June Nasdaq 100 E-Mini futures (NQM2 3) are down -0.21%. U.S. stock index futures this morning are moderately lower as the markets await any new developments on the debt ceiling stalemate. President Biden will meet...

The Independent UK

Pharmaceutical executives challenge Texas court’s abortion pill ruling

Gilead Sciences and Pfizer join amicus brief

StockNews.com

2 Biotech Stocks to Buy Hand Over Fist in March

The biotech industry is expected to expand rapidly, driven by significant advancements and government initiatives. Furthermore, this sector tends to be relatively defensive and holds up relatively well during downturns. So, fundamentally sound biotech stocks Gilead Sciences (GILD) and Vertex Pharmaceuticals (VRTX) might be ideal buys now. Keep reading.

StockNews.com

3 Dividend Paying Stocks to Buy in March

With the stock market anticipated to stay volatile due to persistent concerns about high inflation, interest rate hikes, and a recession, fundamentally solid dividend stocks Gilead Sciences (GILD), CVS Health (CVS), and Altria (MO) might be great buys for a steady income stream. Keep reading.

StockNews.com

It’s Time to Buy Up These 3 Growth Stocks In 2023

While higher rates have hurt growth stocks last year, 2023 could be the year of growth stocks gaining momentum. Amid rising optimism, investors could consider buying fundamentally strong growth stocks Gilead Sciences (GILD), Jazz (JAZZ), and Masonite International (DOOR) this year. Keep reading.

StockNews.com

2 Biotech Stocks to Buy and 1 to Avoid Like the Plague

The biotech industry is expected to witness solid growth driven by growing government initiatives and increasing demand across several sectors. While we think fundamentally sound biotech stocks Gilead Sciences (GILD) and United Therapeutics (UTHR) could be solid buys this year, Bionano Genomics (BNGO) could be best avoided considering its fundamental…

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.